These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32812029)

  • 1. Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota.
    Mavragani CP; Nezos A; Dovrolis N; Andreou NP; Legaki E; Sechi LA; Bamias G; Gazouli M
    Inflamm Bowel Dis; 2020 Sep; 26(10):1543-1553. PubMed ID: 32812029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy.
    Schierova D; Roubalova R; Kolar M; Stehlikova Z; Rob F; Jackova Z; Coufal S; Thon T; Mihula M; Modrak M; Kverka M; Bajer L; Kostovcikova K; Drastich P; Hercogova J; Novakova M; Vasatko M; Lukas M; Tlaskalova-Hogenova H; Jiraskova Zakostelska Z
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients.
    Alatawi H; Mosli M; Saadah OI; Annese V; Al-Hindi R; Alatawy M; Al-Amrah H; Alshehri D; Bahieldin A; Edris S
    Bosn J Basic Med Sci; 2022 Jun; 22(3):412-426. PubMed ID: 34761733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).
    Vatn S; Carstens A; Kristoffersen AB; Bergemalm D; Casén C; Moen AEF; Tannaes TM; Lindstrøm J; Detlie TE; Olbjørn C; Lindquist CM; Söderholm JD; Gomollón F; Kalla R; Satsangi J; Vatn MH; Jahnsen J; Halfvarson J; Ricanek P;
    Scand J Gastroenterol; 2020 Oct; 55(10):1146-1156. PubMed ID: 32780604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment.
    Sanchis-Artero L; Martínez-Blanch JF; Manresa-Vera S; Cortés-Castell E; Valls-Gandia M; Iborra M; Paredes-Arquiola JM; Boscá-Watts M; Huguet JM; Gil-Borrás R; Rodríguez-Morales J; Cortés-Rizo X
    Sci Rep; 2021 May; 11(1):10016. PubMed ID: 33976272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
    Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
    J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment.
    Busquets D; Oliver L; Amoedo J; Ramió-Pujol S; Malagón M; Serrano M; Bahí A; Capdevila M; Lluansí A; Torrealba L; Peries L; Chavero R; Gilabert P; Sàbat M; Guardiola J; Serra-Pagès M; Garcia-Gil J; Aldeguer X
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S63-S66. PubMed ID: 34791288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases.
    Dulic S; Toldi G; Sava F; Kovács L; Molnár T; Milassin Á; Farkas K; Rutka M; Balog A
    Arch Immunol Ther Exp (Warsz); 2020 Apr; 68(2):12. PubMed ID: 32248339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease.
    Lucendo AJ; Roncero Ó; Serrano-Duenas MT; Hervías D; Alcázar LM; Miriam-Ruiz-Ponce ; Verdejo C; Laserna-Mendieta E; Lorente R; Arias Á
    Dig Liver Dis; 2020 Apr; 52(4):400-407. PubMed ID: 31892506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases.
    Dovrolis N; Michalopoulos G; Theodoropoulos GE; Arvanitidis K; Kolios G; Sechi LA; Eliopoulos AG; Gazouli M
    Microorganisms; 2020 Mar; 8(3):. PubMed ID: 32244928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
    Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
    Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
    Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
    Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
    EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional intraepithelial lymphocyte changes in inflammatory bowel disease and spondyloarthritis have disease specific correlations with intestinal microbiota.
    Regner EH; Ohri N; Stahly A; Gerich ME; Fennimore BP; Ir D; Jubair WK; Görg C; Siebert J; Robertson CE; Caplan L; Frank DN; Kuhn KA
    Arthritis Res Ther; 2018 Jul; 20(1):149. PubMed ID: 30029674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Radhakrishnan ST; Alexander JL; Mullish BH; Gallagher KI; Powell N; Hicks LC; Hart AL; Li JV; Marchesi JR; Williams HRT
    Aliment Pharmacol Ther; 2022 Jan; 55(1):26-48. PubMed ID: 34751954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases.
    Park YE; Moon HS; Yong D; Seo H; Yang J; Shin TS; Kim YK; Kim JR; Lee YN; Kim YH; Kim JS; Cheon JH
    Sci Rep; 2022 Apr; 12(1):6359. PubMed ID: 35428806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy.
    Reiss Z; Rob F; Kolar M; Schierova D; Kreisinger J; Jackova Z; Roubalova R; Coufal S; Mihula M; Thon T; Bajer L; Novakova M; Vasatko M; Kostovcikova K; Galanova N; Lukas M; Kverka M; Tresnak Hercogova J; Tlaskalova-Hogenova H; Jiraskova Zakostelska Z
    Front Cell Infect Microbiol; 2022; 12():1064537. PubMed ID: 36704107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.
    Chehoud C; Albenberg LG; Judge C; Hoffmann C; Grunberg S; Bittinger K; Baldassano RN; Lewis JD; Bushman FD; Wu GD
    Inflamm Bowel Dis; 2015 Aug; 21(8):1948-56. PubMed ID: 26083617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
    Bank S; Julsgaard M; Abed OK; Burisch J; Broder Brodersen J; Pedersen NK; Gouliaev A; Ajan R; Nytoft Rasmussen D; Honore Grauslund C; Roug S; Galsgaard J; Sprogøe Høyer Finsen D; Lindby K; ; Sørensen J; Larsen L; Rohr Andersen M; Brandslund I; Thomassen M; Green A; Bo Bojesen A; Bek Sørensen S; Vogel U; Andersen V
    Aliment Pharmacol Ther; 2019 Apr; 49(7):890-903. PubMed ID: 30811631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.